Search Results - "Tkaczuk, K. R."

Abstract P5-12-10: Circulating progranulin (GP88) level is associated with both response to therapy and progression of disease in metastatic breast cancer patients by Serrero, G, Hawkins, DM, Hicks, DJ, Tait, N, Yue, B, Tkaczuk, KR

“…Imaging is the method of choice for monitoring of disease response to therapy during and post-treatment in metastatic breast cancer (MBC) patients. However,…”
Get full text

Abstract P1-02-12: Determination of a serum progranulin (GP88/PGRN) level associated with overall survival in metastatic breast cancer patients by Serrero, G, Hawkins, DM, Yue, B, Hicks, D, Tait, N, Tkaczuk, KR

“…Imaging technologies are the methods of choice in the standard of care (SOC) to monitor therapy response in metastatic breast cancer (MBC) patients. However,…”
Get full text

196TiPSGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer by Boni, V, Alemany, C, Meisel, J L, Sinha, R, Sterrenberg, D, Tkaczuk, K H R, Wang, Y, Wang, Z, Han, H S

Get full text

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer by Boni, V., Alemany, C., Meisel, J.L., Sinha, R., Sterrenberg, D., Tkaczuk, K.H.R., Wang, Y., Wang, Z., Han, H.S.

Get full text

A predictive test for therapeutic treatment outcomes of advanced gastrointestinal cancer patients (AGC) by Pandya, N. B., Tkaczuk, K. R., Tait, N., Ioffe, O., Tan, M., Van Echo, D. A., Sutula, M. J., Lesko, S. A., Deamond, S. F., Ts’o, P. O.

“…Abstract only e15079 Background: There are currently limited options for selecting an optimal treatment regimen for AGC patients. The Drug Response Indicator…”
Get full text

Abstract P5-09-05: Progranulin (GP88) expression and letrozole resistance in breast cancer by Serrero, G, Dong, J, Yue, B, Tkaczuk, KR, Chumsri, S, Hayashi, J

“…The 88 kDa glycoprotein GP88 (Progranulin, PCDGF, acrogranin) is the largest member of the granulin/epithelin family of growth modulators. GP88 was originally…”
Get full text

Abstract P1-03-06: Improvement in risk predictive value of Nottingham prognostic index by determining GP88 tumor tissue expression for estrogen receptor positive breast cancer patients by Serrero, G, Hawkins, DM, Bejarano, PA, Ioffe, O, Tkaczuk, KR, Elliott, RE, Head, JF, Phillips, J, Godwin, AK, Weaver, J, Hicks, D, Yue, B

“…Background: The Nottingham Prognostic Index (NPI), which includes nodal status, tumor size and histological grade was established to provide predictive value…”
Get full text

Abstract P2-10-40: Correlation between expression of the prognostic marker Progranulin (GP88) with Oncotype Dx Recurrence Score in estrogen receptor positive breast tumors by Serrero, G, Koka, M, Goicochea, L, Tkaczuk, KR, Fernandez, KL, Logan, LS, Tuttle, K, Yue, B, Ioffe, OB

“…Background: GP88 (Progranulin, acrogranin) is an 88kDa glycoprotein overexpressed in breast tumors and involved in their proliferation and survival. Biological…”
Get full text

A retrospective study of drug response indicator test (DRIT) as a predictive test for therapeutic treatment outcomes of advanced breast cancer patients (ABC) by Tkaczuk, KR, Tait, NS, Ioffe, O, Rogers, W, Tan, M, Lesko, SA, Lum, ZP, Deamond, SF, Shan, E, Daniel, JR, VanEcho, DA, Ts'o, PO

“…Abstract #6075 We conducted a retrospective study of DRIT, an investigational diagnostic test to predict chemotherapy and endocrine therapy treatment outcomes…”
Get full text